Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

The investment will primarily facilitate the therapy's development ... The company is preparing to progress the drug into a registrational Phase III trial. It aims to engage with the US Food ...

The investment of over $6 million will expand LGM Pharma’s Rosenberg, Texas manufacturing facility as part of its Phase I ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...